Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jakarta International Hotels Development Tbk (JIHD) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance

Jakarta International Hotels Development TbkTrade
Tempo Scan Pacific Tbk.Trade

Price performance (Past 24H)

Key statistics

Jakarta International Hotels Development Tbk vs Tempo Scan Pacific Tbk. — how do they compare? Jakarta International Hotels Development Tbk trades at Rp450 (market cap 1.05T, 73.6K 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,730 (market cap 12.36T, 1.41M 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 11.8× Jakarta International Hotels Development Tbk's market cap, and Tempo Scan Pacific Tbk. is more actively traded (1.41M versus 73.6K). Which is the better fit depends on your goals.

JIHDTSPC
Market Cap
1.05T12.36T
Volume
73.6K1.41M
Lot
73614.08K
Turnover
33.02M3.83B
Average Price
448.662,722.04
Value
33.02M3.83B
Indicative Equilibrium Price
2,730
Indicative Equilibrium Volume
2.51K

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JIHD
View details
TSPC
View details

About Jakarta International Hotels Development Tbk

PT Jakarta International Hotels and Development Tbk (the Company) was established on November 7, 1967. The Company is the owner of Hotel Borobudur (“the Hotel”) which had been managed and operated by Inter-Continental Hotels (Indonesia) BV (Operator) until December 31, 1998. Starting January 1, 1999, the Hotel has been operated by PT Dharma Harapan Raya 60% of whose shares are owned by the Company.

Read more on JIHD

About Tempo Scan Pacific Tbk.

PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.

Read more on TSPC